Shares of Orexigen (OREX +16.7%) are soaring after Credit Suisse initiates coverage with an Outperform, saying it likes the prospects of a trial that will look at the cardiovascular impact of Contrave. Leerink Swann also recommends investors buy it aggressively. Meanwhile, it starts Arena Pharmaceutical (ARNA -4.6%) with an Underperform , saying Belviq may not generate enough revenue to justify the stock's current valuation.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Feb 25, 2015)
at Benzinga.com (Jan 14, 2015)
at CNBC.com (Jan 13, 2015)
at Benzinga.com (Jan 12, 2015)
at Benzinga.com (Jan 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs